Machine Learning

A new national agreement brings QuVa Pharma's AI-powered drug diversion software to thousands of hospitals, promising a high-tech solution to a hidden crisis.

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.

A biotech firm is making waves with a non-viral, redosable gene delivery system showing promise for DMD and hemophilia, challenging the industry's reliance on viruses.

With a star-studded new advisory board, Pilatus Biosciences accelerates its attack on cancer's metabolic defenses with its lead drug, PLT012.

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

Minerva Neurosciences launches a pivotal Phase 3 trial for roluperidone, a potential first-in-class drug for the untreated negative symptoms of schizophrenia.

Commvault showcases its unified, AI-enabled platform at Red Hat Summit, aiming to secure hybrid cloud workloads in a booming container market.

HealthVerity's acquisition of Symphony Health unites clinical and commercial data, promising to shatter industry silos and accelerate medical breakthroughs.

New research reveals AI is not just hype for manufacturers. Early adopters see real value in months, leaving hesitant competitors far behind.

Innovative Dining Group used AI to capture 5,100+ missed calls and book 1,200+ tables, showcasing how automation is now a key ingredient for profit.

A new partnership aims to end the 'black box' era of crypto market making, forcing a shift from reputation to verifiable, data-driven performance.

A new partnership aims to replace perception with performance data, allowing crypto projects to vet liquidity partners with unprecedented clarity.

HURST Jaws of Life and Elevat launch Captium IQ, an AI-powered system designed to ensure mission-critical rescue equipment is always ready for action.

With its 100th study launch and a perfect client retention rate, Atreo's agile RTSM platform is challenging the rigid, slow pace of traditional trial tech.

With new strategic financing and powerhouse board appointments, 4D Path is accelerating its novel AI platform that predicts cancer treatment success from a single slide.

A new firm will underwrite a $400M fund, signaling a shift in patent finance toward specialized expertise and empowering small inventors.

BMW Group and Quantinuum expand their landmark collaboration, leveraging next-gen quantum computers to revolutionize materials for future electric and fuel cell vehicles.

Germany's startups attracted €1.7B in Q1 2026, fueled by US investors and a massive bet on artificial intelligence, signaling a new era for its ecosystem.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

A new biotech emerges with a promising, late-stage gene therapy for Sanfilippo syndrome, offering a potential lifeline for children with no other options.